Tigatuzumab is a humanized IgG1 monoclonal antibody that targets DR5. Tigatuzumab binds to DR5 and trigger apoptosis in tumor cells via downstream caspase activation. Tigatuzumab has been used in the research of cancer therapy.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.